The shifting landscape of diabetes care in Britain
Ask anyone managing diabetes in the UK and they will tell you the same thing: the system is under strain. Around 4.9 million people in the country live with the condition, most of them with type 2. GP appointments are short, waiting lists are long, and the sheer volume of daily decisions about food, exercise, insulin and blood sugar can feel overwhelming.
Yet behind those clinic waiting rooms, something significant is happening. The UK has quietly become one of the busiest places in Europe for diabetes management trials. Universities like Oxford, Manchester and Cambridge, working alongside the NHS and Diabetes UK, are testing everything from total diet replacement programmes to fully automated insulin systems. The results are not staying in academic journals either. They are changing what your own clinic can offer within a year or two.
That gap between what researchers know and what patients hear is the real problem. Most eligible people never learn about a study in time, or they assume trials mean risky untested treatments. The reality is often the opposite: many diabetes management trials in the UK offer structured support, regular monitoring and access to technology that would otherwise take years to reach you through standard care.
What the latest trials are actually testing
The most talked-about programme right now is the NHS Type 2 Diabetes Path to Remission, sometimes called the soups and shakes plan. It grew out of the DiRECT trial, a landmark study that showed around 46% of participants achieved remission at one year and 36% at two years by following a low-calorie total diet replacement for a set period, then reintroducing food gradually. Recent NHS data shows record numbers of people have now gone through the programme, and it continues to expand across England. The catch, as researchers are quick to point out, is that many eligible people do not take it up in the first place.
That is exactly what the NewDAWN trial from the University of Oxford is trying to solve. Instead of offering one rigid route, NewDAWN tests whether giving people a choice of weight loss programmes increases uptake and leads to more remission overall. It is recruiting 1,788 adults diagnosed with type 2 diabetes within the past six years, and it compares the adaptive approach against the standard Path to Remission pathway across twelve separate outcomes, including cost effectiveness. For participants, that means being offered options rather than a single prescriptive plan.
For people with type 1 diabetes, the action has shifted to technology. The FLASH-UK study demonstrated that intermittently scanned continuous glucose monitoring improves blood sugar control in adults who test with finger pricks, and its findings have fed directly into NICE guidance. Building on that, the NHS England hybrid closed-loop pilot has been rolling out automated insulin delivery systems to eligible patients. A recent meta-analysis pooling 27 randomised trials and more than 1,000 participants confirmed that hybrid closed-loop systems beat sensor-augmented pumps on time in range and glucose variability. Meanwhile the INSIGHT-1 study, which started recruiting in May and runs until mid-2027, is examining whether closed-loop pump therapy affects diabetic retinopathy over 24 months in adults with type 1 diabetes.
Real-world evidence matters as much as randomised trials here. A prospective study using the simplified Dexcom ONE continuous glucose monitor followed a socioeconomically diverse group of adults with suboptimal control who used two or more insulin injections a day. Over the study period, HbA1c improved significantly, and the authors argued that more people should qualify for this technology under current guidelines.
| Study or programme | What it tests | Who can join | How it is funded | Main advantages | Things to weigh up |
|---|
| NHS Path to Remission | Total diet replacement for type 2 remission | Adults with recent type 2 diagnosis who are overweight | Provided through NHS care | Strong evidence base, structured support | Requires real commitment to the diet phase |
| NewDAWN trial (Oxford) | Offering a menu of weight loss options vs one standard plan | 1,788 adults with type 2 diabetes diagnosed in the last six years | Covered by the trial | Personalised choice, longer-term follow-up | Multi-year commitment to data collection |
| FLASH-UK follow-on | Flash glucose monitoring in type 1 diabetes | Adults with type 1 diabetes | NHS-funded where eligible | Fewer finger pricks, better control data | Sensors need replacing regularly |
| NHS hybrid closed-loop pilot | Automated insulin delivery systems | Eligible adults with type 1 diabetes | NHS-funded in pilot areas | Improved time in range, less variability | Training and troubleshooting required |
| Dexcom ONE real-world study | Simplified continuous glucose monitoring | Insulin users with suboptimal control | Devices provided for the study | Broad eligibility, real-life settings | Study period is time-limited |
Making trial participation work for real life
Research only helps people if the findings survive contact with everyday life, and the UK trials have been built with that in mind.
Sarah, a 54-year-old school administrator from Leeds, was diagnosed with type 2 diabetes two years ago. Her practice nurse mentioned the Path to Remission programme, but Sarah assumed she would have to give up all food she enjoyed and fail within a week. What changed her mind was a phone call from the practice explaining the structure: the total diet replacement phase is temporary, the meal reintroduction is guided, and a coach checks in regularly. She finished the programme within the target timeframe, reduced her diabetes medication, and her latest HbA1c has come down to a level her clinician described as encouraging. For Sarah, the deciding factor was that someone walked her through the steps before she committed.
James, a 29-year-old engineer in Manchester with type 1 diabetes, took a different route. He joined a study linked to the hybrid closed-loop rollout after his consultant flagged it during a routine review. The trial supplied the pump system, and the research team handled the setup and training over a series of visits. Within months his time in range improved noticeably, and he says the biggest change was waking up without the overnight anxiety that had become normal. Not every study suits every person, but both stories share a common thread: the research teams did the heavy lifting on logistics, and the participants simply had to turn up.
The practical advice from people who have been through these programmes is consistent. Keep a blood sugar and food diary for at least two weeks before you enquire, because clinics use real data to match you to the right study. Ask about the follow-up schedule before you sign anything, and check what happens at the end of the trial, such as whether funded technology continues. Bring a partner or friend to the screening appointment if you can, since two sets of ears help when the consent form gets detailed.
How to get involved in a diabetes management trial in the UK
Finding the right study is easier than most people expect, once you know where to look.
Start with your GP or diabetes specialist nurse. Practices connected to research-active networks can refer you directly to studies they are running or know about. The NHS also maintains a searchable register of ongoing research, and many university diabetes centres publish their recruitment pages openly. Charities like Diabetes UK list patient-facing research opportunities and explain in plain language what each study involves, which is useful when the medical jargon gets dense.
Before you apply, run through three questions. Is the study asking for participants who match your type of diabetes, your treatment and your recent HbA1c? Are the time commitments realistic given your work and family life? And does the trial offer clear communication about results and follow-up care? A well-run study should be happy to answer all three before you consent.
Location matters less than it used to, because several recent UK trials have moved to hybrid models with remote monitoring and fewer clinic visits. That said, being near a major diabetes centre in places like Manchester, Leicester, London or Glasgow still widens your options considerably, particularly for technology studies that need in-person device fitting.
One more thing worth knowing: participation in NHS-linked trials does not require any payment, and reasonable travel costs are usually reimbursed. No one should be out of pocket for helping to improve diabetes care for everyone else.
A gentle nudge towards taking the first step
You do not need to understand every detail of a trial protocol to benefit from one. You just need to know that the option exists and that asking a single question at your next review could open a door. Whether it is the structure of the Path to Remission programme, a flash glucose monitor for type 1 diabetes, or a closed-loop system that lightens the mental load of insulin dosing, the evidence building in UK research centres right now will shape what your clinic offers over the next few years.
The people who get the most out of these studies tend to be the ones who ask early, bring their own questions, and treat the trial as a partnership rather than a passive experience. Your next appointment is a reasonable place to start that conversation. Say the words out loud: are there any diabetes management trials I might be eligible for? The answer might surprise you, and the research happening now is better than it has ever been.
研究の知恵